Nicholas J. Maurice
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nicholas J. Maurice has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
- Adam L. Burrack
Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, MN, USA
12 shared publications - Alexander K. Tsai
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA; Center for Immunology, University of Minnesota, Minneapolis, MN 55455, USA
12 shared publications - Antonio B. Rizzo
Center for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota
12 shared publications - Audrey L. Hilk
Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, MN, USA
12 shared publications - Brandon M. Larsen
Center for Immunology, University of Minnesota Medical School, Minneapolis, Minnesota
12 shared publications - Cara-Lin Lonetree
Department of Microbiology and Immunology, University of Minnesota Medical School, Minneapolis, MN, USA
12 shared publications
Latest Publications
- Open Access
- 23 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (13)
KLF2 overrides the resident memory CD8 T cell differentiation program, in opposition to KLF3
Numerous transcriptional regulators have been associated with the differentiation pathways that lead to recirculating vs. tissue-resident memory T cells. However, it is unclear whether independent, coordinated expression of these regulators is required to determine residency vs. recirculation or whether there is a hierarchy, with some factors playing a dominant role in controlling T cell trafficking. We report that ablation of the gene encoding Kruppel-like factor 2 (KLF2) during CD8 + T cell activation leads to rapid transcriptional reprogramming, such that effector T cells fail to recirculate and prematurely acquire canonical phenotypic and transcriptional characteristics of resident memory cells (T RM ). Klf2 -deficient memory CD8 + T cells retained the capacity to undergo recall responses, including in vivo pathogen control. These data suggest that KLF2 diverts CD8 + T cells from the T RM differentiation program. In contrast, ablation of another member of the KLF family, KLF3, enhanced differentiation of some recirculating T cell subsets and limited production of T RM in lymphoid tissues. However, both KLF2 and KLF3 were required for differentiation of long-lived effector cells, suggesting cooperation between these factors in some situations. These findings indicate that KLFs occupy a central nexus in coordinating activated CD8 + T cell differentiation and trafficking.
- 23 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (13)
Open AccessKLF2 overrides the resident memory CD8 T cell differentiation program, in opposition to KLF3
Numerous transcriptional regulators have been associated with the differentiation pathways that lead to recirculating vs. tissue-resident memory T cells. However, it is unclear whether independent, coordinated expression of these regulators is required to determine residency vs. recirculation or whether there is a hierarchy, with some factors playing a dominant role in controlling T cell trafficking. We report that ablation of the gene encoding Kruppel-like factor 2 (KLF2) during CD8 + T cell activation leads to rapid transcriptional reprogramming, such that effector T cells fail to recirculate and prematurely acquire canonical phenotypic and transcriptional characteristics of resident memory cells (T RM ). Klf2 -deficient memory CD8 + T cells retained the capacity to undergo recall responses, including in vivo pathogen control. These data suggest that KLF2 diverts CD8 + T cells from the T RM differentiation program. In contrast, ablation of another member of the KLF family, KLF3, enhanced differentiation of some recirculating T cell subsets and limited production of T RM in lymphoid tissues. However, both KLF2 and KLF3 were required for differentiation of long-lived effector cells, suggesting cooperation between these factors in some situations. These findings indicate that KLFs occupy a central nexus in coordinating activated CD8 + T cell differentiation and trafficking.
- 10 February 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (3) , 476-489
IL-4–STAT6 signaling delays protective CD8+ T cell bystander activation by antagonizing IL-18 sensing
Memory CD8+ T (Tmem) cells are activated into innate-like killers by cytokines, including interleukin-12 (IL-12), IL-15 and IL-18; but mechanisms regulating this phenomenon (termed bystander activation) are unclear. Here we show that basal IL-4 signals antagonize IL-18 sensing and subsequent interferon-γ production during Tmem cell bystander activation. IL-4 treatment can act directly on Tmem cells in a STAT6-dependent manner to limit interferon-γ-mediated control of a bystander bacterial infection. IL-4 does not simply block bystander activation but tunes effector molecule expression. Strain-specific defects in bystander activation of homeostatic Tmem cells partially relates to IL-4 exposure, but these differences are erased in Tmem cells produced by T cell antigen receptor activation, leading to uniform IL-18 receptor expression and capacity for bystander activation/cytotoxicity. Our data demonstrate that bystander activation by inflammatory cytokines is subject to regulation by both IL-4 and prior antigen experience. These findings underscore the importance of the cytokine milieu in dictating bystander-mediated pathogen control.
- 10 February 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (3) , 476-489
IL-4–STAT6 signaling delays protective CD8+ T cell bystander activation by antagonizing IL-18 sensing
Memory CD8+ T (Tmem) cells are activated into innate-like killers by cytokines, including interleukin-12 (IL-12), IL-15 and IL-18; but mechanisms regulating this phenomenon (termed bystander activation) are unclear. Here we show that basal IL-4 signals antagonize IL-18 sensing and subsequent interferon-γ production during Tmem cell bystander activation. IL-4 treatment can act directly on Tmem cells in a STAT6-dependent manner to limit interferon-γ-mediated control of a bystander bacterial infection. IL-4 does not simply block bystander activation but tunes effector molecule expression. Strain-specific defects in bystander activation of homeostatic Tmem cells partially relates to IL-4 exposure, but these differences are erased in Tmem cells produced by T cell antigen receptor activation, leading to uniform IL-18 receptor expression and capacity for bystander activation/cytotoxicity. Our data demonstrate that bystander activation by inflammatory cytokines is subject to regulation by both IL-4 and prior antigen experience. These findings underscore the importance of the cytokine milieu in dictating bystander-mediated pathogen control.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma
Antigen specificity and functionality of predominant TCRs from tumors from immunotherapy treated mice.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma
Antigen specificity and functionality of predominant TCRs from tumors from immunotherapy treated mice.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma
Single cell transcriptional atlas following anti-PDL1 or agonistic anti-CD40
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma
Single cell transcriptional atlas following anti-PDL1 or agonistic anti-CD40
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma
CD4 T cells and tumor antigen are required for anti-CD40 driven TSTEM accumulation in PDA
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma
CD4 T cells and tumor antigen are required for anti-CD40 driven TSTEM accumulation in PDA
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma
Comparison of human and murine tumor-infiltrating CD8 T cells.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma
Comparison of human and murine tumor-infiltrating CD8 T cells.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma
IL15C synergizes with immunotherapy to target poorly immunogenic KPC2 tumors
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma
IL15C synergizes with immunotherapy to target poorly immunogenic KPC2 tumors
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma
CD8 T cell differentiation in PDA.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma
CD8 T cell differentiation in PDA.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary FIgure 8 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma
IL-15C promotes the activity of dual therapy by promoting T-bet in tumor-infiltrating T cells
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary FIgure 8 from IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma
IL-15C promotes the activity of dual therapy by promoting T-bet in tumor-infiltrating T cells